Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 extension study of Vi-CRM197 booster after priming with Vi-CRM197 or Typherix
2011-001448-31Phase 2Completed
- Sponsor
- Novartis
- Start
- Jul 2011
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of Vi-CRM197 in typhoid fever (2 arms), sponsored by Novartis. Primary endpoint: Immunogenicity Endpoints. Started Jul 2011; status: completed.
02
Drugs
Vi-CRM197
03
Conditions
typhoid fever
Beyond the preview
Go deeper on 2011-001448-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001448-31.